The c-MYB transcription factor is a key regulator of hematopoietic cell proliferation and differentiation, and dysregulation of c-MYB activity often associates with various hematological disorders. Yet, its pathogenic role remains largely unknown due to lack of suitable animal models. Here, we report a detail characterization of a c-myb-gfp transgenic zebrafish harboring c-Myb hyperactivity (named c-myb hyper ). This line exhibits abnormal granulocyte expansion that resembles human myelodysplastic syndrome (MDS) from embryonic stage to adulthood. Strikingly, a small portion of c-myb hyper adult fish develops acute myeloid leukemia-like or acute lymphoid leukemia-like disorders with age. The myeloid and lymphoid malignancies in c-myb hyper adult fish are likely caused by the hyperactivity of c-myb, resulting in the dysregulation of a number of cell-cycle-related genes and hyperproliferation of hematopoietic precursor cells. Finally, treatment with c-myb target drug flavopiridol can relieve the MDS-like symptoms in both c-myb hyper embryos and adult fish. Our study establishes a zebrafish model for studying the cellular and molecular mechanisms underlying c-Myb-associated leukemogenesis as well as for anti-leukemic drug screening.
INTRODUCTION
The proto-oncogene c-myb is a master regulator essential for proliferation and differentiation of hematopoietic cells during normal hematopoiesis.
1,2 Studies of c-MYB-deficient mice and zebrafish have revealed that c-MYB plays essential roles in various stages of hematopoiesis, including hematopoietic stem cell (HSC) development, 3 erythropoiesis, 4 myelopoiesis 5 and lymphopoiesis. 6, 7 The importance of c-MYB is exemplified by its involvement in hematological diseases in animals and humans. Aberrant activation or ectopic expression of c-MYB in vitro has been shown to contribute to the transformation of hematopoietic progenitors into leukemic cells. 8 In avian and in mice, c-MYB truncated by virus targeting often leads to its aberrant activity, and causes leukemia transformation. 9, 10 Conversely, suppression of c-MYB activity in mice inhibits aggressive acute myelogenous leukemia (AML). 11 Clinically, c-MYB has been found to be highly expressed in leukemic cells in patients with AML, chronic myeloid leukemia and acute lymphoblastic leukemia (ALL), and it is essential for the proliferation and maintenance of leukemic cells. 2, 12, 13 Several recent reports have identified genetic lesions, including chromosomal translocation, 14 genomic duplication 15 and mutations, 16 that alter the c-MYB activity in human lymphoid and myeloid leukemias. Collectively, these studies have documented that c-MYB plays a key role in human leukemogenesis. However, the molecular basis underlying c-MYB-associated leukemogenesis remains undefined and effective treatment for leukemia patients with aberrant c-MYB activity is still lacking.
Zebrafish, which share high similarities in blood contents and genetic regulatory networks to mammals, 17 have emerged as an excellent model organism for studying the pathogenesis of some hematological disorders 18 as well as for drug discovery. 19 Despite increasing numbers of zebrafish models with hematologic malignancies have been generated by mutagenesis or by overexpressing key oncogenic proteins in the past several years, 20 ,21 a zebrafish malignant model associated with c-MYB hyperactivity remains unavailable.
Here, we investigated the induction of myeloid and lymphoid leukemia in transgenic zebrafish with c-myb hyperactivity. We found that a c-myb-gfp transgenic zebrafish line generated previously 22 overexpresses WT c-Myb and a hyperactive fusion c-Myb because of the duplication of the c-myb locus. The c-myb-overexpressing zebrafish, referred as to c-myb hyper (c-myb with hyperactivity), display hematopoietic perturbation at the embryonic stages and can develop myeloid and lymphoid leukemia-like phenotypes in adulthood. Our findings show that c-Myb functions as a driver for leukemogenesis in vivo by promoting hematopoietic cell proliferation and the c-myb hyper zebrafish may serve as a suitable animal model for anti-leukemia drug screening. 1 
MATERIALS AND METHODS

Zebrafish husbandry
All experiments involving zebrafish were performed in accordance with the guidelines laid down by the Institutional Animal Care and Use Committee of Southern Medical University. Zebrafish (3 days-24 months old) of either sex were maintained as described previously. 23, 24 The following strains were used: AB, c-myb-gfp, 22 c-myb hkz3 (a loss-of-function c-myb mutant), 25 rag2-dsRed 26 and lyz-dsRed.
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Whole-mount in situ hybridization
Whole-mount in situ hybridization was performed with antisense digoxigenin-labeled RNA probes, according to standard protocols. 28 Sudan black staining Fixed embryos were incubated in Sudan black B (Sigma-Aldrich, St Louis, MO, USA; 199664) solution and washed as described previously. 29 
Leukemia transplantation
Leukemic cell suspensions were prepared from c-myb hyper /lyz-dsRed (myelodysplastic syndrome (MDS)-like), c-myb hyper (AML-like) or c-myb hyper /rag2-dsRed (ALL-like) fish as previously described. 20 Two days after receiving a sublethal dose of radiation (25 Gy), 0.2 million cells were injected intracardially into the irradiated recipients using a glass capillary needle (World Precision Instruments, Sarasota, FL, USA; 1B100-6). 
Cytological analysis
Peripheral blood (PB) and kidney marrow (KM) were re-suspended in ice-cold phosphate-buffered saline with 5% fetal bovine serum, followed by cytospins at 400 r.p.m. for 3 min. The cells were then stained with Giemsa (Merck, Darmstadt, Germany; 1.09204.0500) and May-Grunwald's eosin methylene blue (Merck; 1.01424.0500) according to the manufacturer's instructions. Blood cells of KM and PB were calculated manually based on their morphologies. 30 Treatment with chemotherapeutic agents Embryos were soaked in egg water containing cytarabine (Pfizer, Milano, Italy), quizartinib (LC Laboratories, Woburn, MA, USA) or flavopiridol (Santa Cruz, Dallas, TX, USA; sc-202157) for drug treatment. Adult fish were intraperitoneally injected with cytarabine (600-2000 mg/kg) and flavopiridol (30-130 mg/kg) once daily for 4 days. The doses for intraperitoneal injection were based on the trials in murine models, 31, 32 and 4-20-fold higher doses were applied in adult fish.
Statistical analysis
The differences between categorical variables were analyzed by Fisher's exact tests. Continuous variables were compared by two-tailed Student's t-tests. In all graphs, error bars reflect mean ± s.d. A P-value less than 0.05 was considered significant. P-values were not adjusted for multiple comparisons and the variation was similar between the groups that were compared. No statistical methods were used to predetermine sample size. The sample size was determined based on numbers reported in previous studies and no samples were excluded. Experiments were not randomized, and investigators were not blinded to allocation during experiments and outcome assessment.
RESULTS
Two different c-myb transcripts, a wild-type and a truncated form, are produced from the c-myb PAC in the c-myb-gfp transgenic line North et al. 22 have described the generation of a c-myb-gfp transgenic zebrafish line for labeling c-myb-positive hematopoietic stem cells. Unexpectedly, when examined the phenotype of c-myb hkz3 − / − ; c-myb-gfp +/ − embryos, we found that the c-myb hkz3 − / − mutant phenotypes were completely rescued (data not shown). This result prompted us to speculate that a functional c-Myb must be produced in the c-myb-gfp transgenic line. Consistent with this idea, wholemount in situ hybridization staining showed that c-myb expression in the aorta-gonad-mesoderm, caudal hematopoietic tissue and kidney was significantly increased in c-myb-gfp transgenic line compared with that in WT control fish (Figure 1a) , suggesting c-myb might be overproduced in this line. To prove this is indeed the case, we sequenced the c-myb PAC in c-myb-gfp transgenic fish and found two duplicated sequences in the modified c-myb PAC: a 485-bp sequence (including a 315-bp core promoter region and a 170-bp 5′ UTR of c-myb) inserted before the translation start site (Figure 1b and Supplementary Figure S1A) ; and a large region from pWSMK-T vector to c-myb intron 10 inserted into the breakpoint within intron 10 ( Figure 1b and Supplementary Figure S1B ). 5′ and 3′-rapid amplification of cDNA ends analysis revealed that two different c-myb transcripts were produced from the c-myb PAC in the c-myb-gfp transgenic fish (Figure 1c and Supplementary Figure S1C) . One transcript c-myb-WT was produced from the second c-myb core promoter and was identical to the endogenous c-myb (Figure 1c) . The other transcript c-myb-T1 (4.3 kb), generated from the first c-myb core promoter, comprised of a truncated c-myb (from exon 1 to exon 10) followed by a near full-length c-myb (from exon 2 to exon 15) (Figure 1c) . The c-myb-T1 transcript is predicted to produce a large fusion protein, in which a truncated c-Myb lacking the majority of negative-regulatory region 33 is fused with a nearly full-length c-Myb (lacking the first 8 aa) (Figure 1c and Supplementary Figure S1D ).
Quantification analysis indicated that the ratio of endogenous c-myb, transgenic c-myb-WT and c-myb-T1 in the KM of adult c-myb-gfp transgenic fish was 1:5:2 (Figure 1d ), confirming that c-myb transcripts are indeed overproduced in the c-myb-gfp transgenic line. As c-Myb-T1 fusion protein contains a truncated c-Myb lacking the inhibitory domain, we reasoned that the c-Myb-T1 had a higher transactivation activity as previously reported in mammals. 33 Indeed, luciferase reporter assay confirmed that c-Myb-T1 displayed a higher transactivation activity in activating the lect2l gene promoter (the zebrafish ortholog of the chicken c-Myb target gene min-1
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) than c-Myb-WT (Supplementary Figure S1E) . Thus, the c-myb-gfp transgenic fish appears to produce higher level of c-Myb-WT and a hyperactive truncated c-Myb-T1 and it is therefore referred as to c-myb
Aberrant c-myb hyperactivity results in accumulation of abnormal granulocytes in early development It has been shown that the appropriate levels of c-Myb are important for regulating the distinct differentiation steps during hematopoietic cell development, 35 and aberrant c-MYB activities have been known to associate with human myeloid leukemia. 36, 37 We therefore explored the effects of aberrant c-Myb production on myeloid cell development in c-myb hyper embryos and larvae using lineage-specific markers. We found that early myeloid markers, c/epba (CCAAT/enhancer-binding protein a) 38 and lcp (lymphocyte cytosolic protein 1), 39 were increased in c-myb hyper embryos (Supplementary Figures S2A and B) . Likewise, the expression of granulocytic markers, lyz (lysozyme C) 40 and mpx (myeloid-specific peroxidase), 41 was also elevated ( Figure 2a and Supplementary Figure S2C ). In contrast, the macrophage lineage markers, mfap4 (microfibrillar-associated protein 4) 42 and c-fms (colony-stimulating factor-1 receptor), 43 did not show obvious increase in c-myb hyper embryos (Supplementary Figures S2D and E) . These data suggest a robust expansion of granulocytic lineage in c-myb hyper embryos. This was further supported by the increased Sudan black (SB) staining, which preferentially marks granulocytes in zebrafish, 44 in the caudal hematopoietic tissue and KM in c-myb hyper larvae (Figures 2b-d) . Notably, the SB + granulocytes in c-myb hyper appeared to be larger in size and darker in SB staining (Figures 2b and c), compared with their sibling controls, indicating that the increased granulocytic cells perhaps as a result of early developmental defect.
To determine the myeloid cell expansion is attributed to single transcripts generated from the PAC or caused by combination effects of both products, we compared the granulocytic lineage expansion ability of the two forms by ectopically expressing c-myb-WT and c-myb-T1 driven by the same promoter in WT embryos. Consistent with the observation that c-Myb-T1 is hyperactive, we found that under the control of the c-myb mini promoter (Supplementary Figure S1A) , ectopically expressing c-myb-T1 caused a modest increase of SB + granulocytes, while c-myb-WT failed to do so (Figures 2e and f), though the expression of both transcripts is comparable (Figure 2g ). However, overexpressing either c-myb-WT or c-myb-T1 under a stronger ubiquitous promoter (elongation factor-1 alpha promoter, ef1a) was sufficient to induce granulocytic lineage expansion as indicated by SB staining, though the induction by c-myb-T1 was more profound (Supplementary Figures S2F-H ). These data indicate that the myeloid accumulation in c-myb hyper fish is likely to be attributed to additive effects of c-myb-WT and c-myb-T1.
c-myb
hyper adult fish display abnormal myeloid cell expansion resembled MDS-like phenotypes mainly caused by proliferation perturbation MYB hyperactivity has been shown to be main genetic mutations in several types of human lymphoid and myeloid leukemias. Whole-mount in situ hybridization of lyz (a) expression at 3 dpf in c-myb-gfp fish and non-transgenic siblings. SB staining in 3 dpf (b) and 7 dpf (c) larvae. The caudal hematopoietic tissue (CHT) and kidney regions were enlarged in red box (×20). Green boxes (b) show further enlarged region focusing on a single cell (×100). Numbers in each panel indicate the number of embryos with elevated expression of markers out of total number of fish (Fisher's exact tests, Po0.01). SB + cell counts in 3 dpf (d) (t-test, n = 10; mean ± s.d.; *P o0.05, **Po 0.01). (e-g) Ectopically expressed c-myb-WT and c-myb-T1 under the c-myb mini promoter. cDNAs of c-myb-WT-gfp, c-myb-T1-gfp and gfp control driven by c-myb mini promoter were injected into one-cell stage WT embryos, respectively. Representative pictures of SB-positive cell counts in 3 dpf embryos (e). SB + myeloid cell counts (f) and c-myb transcript levels (g) after injection were calculated and compared at 3 dpf (t-test; gfp, c-myb-WT-gfp, c-myb-T1-gfp, n = 21, n = 24 and n = 23, respectively; mean ± s.d.; *P o0.05, **Po 0.01).
collected from 3-month-old and 1-year-old c-myb hyper fish or siblings and subjected to cytological and blood cell count analyses. No significant alterations were observed in PB constituents in c-myb Figures S3E and F) . These results indicate marked myelodysplasia in c-myb hyper fish characterized by elevated cell numbers, enlarged cell size and increased cell granularity, resembled the symptoms of human MDS, composed by a heterogeneous group of clonal hematological disorders that are usually diagnosed based on findings in PB, and especially the bone marrow and characterized by ineffective hematopoiesis, showing dysplastic feature in at least one lineage in the bone marrow. 45 To further determine if their internal organs were affected, c-myb hyper and control fish were dissected and observed under the microscope. The kidneys in 1-year-old c-myb hyper zebrafish appeared swollen, with an enlarged kidney area and almost fourfold increase in kidney weight compared with siblings (Figures 3e-g ). Livers in c-myb hyper fish were also heavier, with enrichment of invaded SB + granulocytes compared with controls (Figures 3h and i) . These defects resembled the effects on organs and invasion observed in myelogenous hematological malignancies. Overall, the blood phenotypes and organ infiltrations in c-myb hyper fish resembled the symptoms of MDS. The myeloid cell accumulation in c-myb hyper fish from embryonic stage to adult could be caused by accelerated proliferation or reduced apoptosis. To clarify the cellular mechanisms responsible for myeloid cell expansion in c-myb hyper fish, we monitored cell proliferation and cell death in neutrophils by bromodeoxyuridine incorporation and terminal dexynucleotidyl transferase (TdT)-mediated dUTP nick end labeling assay, respectively. Myeloid cell apoptosis in c-myb hyper embryos and adult KM was comparable to those in sibling control (Supplementary Figures S3G-J which are known to be or predicted to be the direct targets of c-myb.
As shown in Table 1 , the expression of the cell-cycle-promoting genes ccna1, ccnb1, ccnd1, ccne, ccnh, cdk1, cdk2, cdk7, cdc20 and pcna were upregulated in c-myb hyper MDS KM cells, while the cell-cycle inhibition genes cdkn1c and cdkn2d were downregulated in c-myb hyper MDS KM cells (Table 1) . Collectively, these results indicate that c-myb hyperactivity affects the expression of a cluster of cell-cycle-related genes, resulting in myeloid cell proliferation perturbation.
hyper MDS fish can progress to AML and ALL MDS is the most common hematologic malignancy in the elderly, and approximately one-third of MDS patients will eventually progress to acute leukemia. 51 We were therefore keen to test if adult c-myb hyper fish developed AML or ALL (with myeloblasts or lymphoblasts increased) by analyzing blood cell counts or FACS of a large number of 10-24-month-old adult c-myb hyper fish and siblings. As expected, acute leukemia were never found in 324 of 10-24 months sibling fish. However, 18 AML and 18 ALL were found among 852 of 10-24-month-old c-myb hyper fish ( Table 2 ). The AML-like c-myb hyper fish showed 425% increase in precursors with myeloblasts morphology in the PB or 440% increase of precursors in KM (Figure 4a and Table 2 ), and some of them showed pathologic external features, including abnormal body contour, exophthalmos, bleeding and abdominal mass ( Supplementary  Figures S4C-F) . Moreover, examination of tissue sections of AML-like c-myb hyper fish showed obvious infiltrations of leukemic cells with myeloblast morphology in many non-hematopoietic tissues including liver, muscles and gills (Figure 4b and Supplementary Figure S5A) . The typical granulocytic morphology of the myeloid cells accumulated in the KM (Figure 4a ) and infiltrated in non-hematopoietic tissues (Figure 4b and Supplementary Figure S5A) indicates that c-myb hyper fish could progress to AML with granulocytic origin.
As anticipated, the ALL-like c-myb hyper fish showed 480% increase in lymphocytes or 460% increase in precursors with lymphoblasts morphology in the PB, and a 440% increase in lymphocytes in the KM ( Figure 4c and Table 2 , n = 12 and n = 10, respectively; mean ± s.e.m.; **Po0.01.
Aberrant c-myb activity and leukemia in zebrafish W Liu et al infiltration in ALL human patients. This was further confirmed by using the lymphoid-specific transgenic line rag2-dsRed, 26 in which rag2 + cells were found in the head and the anterior half of the body (Supplementary Figure S5C) . Examination of T-cell (tcrα, the T-cell receptor) and B-cell (igu and iglc3 for immunoglobins) markers in the PB derived from 10 individual ALL-like c-myb hyper fish revealed that six of the fish expressed a high level of T-cell receptor alpha (tcrα) but not B-cell marker, immunoglobins igu and iglc3 (Figure 4e ), whereas the remaining four fish were enriched in the expression of immunoglobins igu and iglc3 but not T-cell marker tcra (Figure 4f ). These results indicate that aberrant c-myb hyperactivity can lead to both T-cell and B-cell ALL.
Collectively, these data demonstrate that c-myb hyper fish (10-24 months) can progress to AML and ALL with the incidence of~2.1%, respectively. The occurrence of AML and ALL appears to be age-dependent as the incidence is much lower in 3-to 10-month-old young adult c-myb hyper fish (~0.5%, only 1 out of 203 fish). Figures S6B and C) . In contrast, none of control fish showed any sign of MDS-like phenotype (Figures 5a-c and Supplementary Figures S6B and C) . For AML, similar protocol was employed with the exception that the donor KM cells were collected from AML-like c-myb hyper fish (fluorescence labeled c-myb hyper AML fish are unavailable) and WT fish as control. As expected, all three survived recipients received cells from two independent AML donors displayed a significant increase of myeloblasts in the KM within 4-6 weeks after transplantation, whereas controls exhibited normal blood composition (Figures 5d  and e) . For ALL transplantation, KM cells were collected from 1-year-old c-myb hyper /rag2-dsRed ALL-like donors or rag2-dsRed controls, in which lymphocytes were marked by dsRed. Within 6-9 weeks after transplantation, all six survived recipients received cells from three different ALL donors displayed ALL-like phenotype as indicated by the robust infiltration of rag2 + lymphoblasts, whereas none of controls developed ALL-like phenotype (Figure 5f ). These data demonstrate that MDS, AML-and ALL-like leukemic cells in c-myb hyper are transplantable.
c-myb hyper leukemic model responds to chemotherapeutic drug treatment Growing evidences have demonstrated that zebrafish is a promising animal model for drug discovery. 19 We therefore evaluated the effects of widely used anti-leukemic agent in c-myb hyper fish. For drug treatment, the tolerance of chemotherapeutic was tested and the maximum dose was used (Supplementary Figure S7A) . Cytarabine 52 is commonly used to treat AML by inhibiting the cell cycle. c-myb hyper embryos and their siblings were incubated with 10 3 mg/l cytarabine at 1 dpf, and the numbers of SB + granulocytic cells were calculated in the caudal hematopoietic tissue at 6 dpf (Figures 6a, b and f) . Results showed that cytarabine treatment significantly reduced the number of SB + granulocytes in c-myb hyper embryos (Figures 6b and f) , compared with the untreated controls (Figures 6a and f) . However, when we performed cytarabine treatment in adult c-myb hyper fish with a 6-20-fold higher than the dose used in mice, 31 no curative effect was observed (Supplementary Figure S7B) . These results indicate that the cell-cycle-specific antiproliferation drug cytarabine can relieve neoplastic proliferation of granulocytes in c-myb hyper embryos but not in adult fish.
To obtain better curative effects, we turned to the c-MYBtargeting drug flavopiridol. 53 Maximum tolerance dose (MTD) (0.5 μM) of flavopiridol significantly reduced the numbers of SB + granulocytes in c-myb hyper embryos compared with the untreated controls (Figures 6c, d and f and Supplementary Figure S7A) . As expected, c-myb RNA levels were also significantly reduced in c-myb hyper embryos upon flavopiridol treatment compared with untreated fish (Figure 6g ). On the other hand, Flt3-targeting drug quizartinib 54 was included as a control and treatment with maximum tolerance dose (0.5 μm) of quizartinib had little effect on the number of SB + granulocytes and the c-myb RNA levels in c-myb hyper embryos (Figures 6c, e and f and Supplementary Figure S7A ). These results indicated that clinically used c-MYBtargeting drug can specifically and effectively reduced the expanded myeloid population in c-myb hyper embryos. To further evaluate the anti-leukemic activity of flavopiridol in adulthood, MDS-like c-myb hyper adult fish were intraperitoneal injected with flavopiridol and phosphate-buffered saline control (once per day) and the number of myeloid cells was quantified 4 days later. 
B-cell
The percentages were indicated by mean ± s.e.m. Adult c-myb hyper fish characterized by 425% precursors with myeloblasts morphology in PB or 440% in KM were divided into AML; and fish characterized by 480% lymphocytes or 460% precursors with lymphoblasts morphology in the PB, and 440% in the KM were divided into ALL. AML-Group I: precursors increased in both PB and KM. AML-Group II: precursors increased in PB. AML-Group III: precursors increased in KM. ALL-Group I: lymphocytes increased in both PB and KM. ALL-Group II: precursors increased in PB and lymphocytes increased in KM (mean ± s.e.m.). a Indicates precursors in PB or KM increased 425% or 40%, respectively, in AML. Indicates lymphocytes in PB or KM increased 480% or 440%, respectively, in ALL.
c Indicates precursors in PB increased 460% in ALL.
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Results showed that a low dose (30 mg/kg/day) of flavopiridol was able to significantly reduce the number of myeloid cells in c-myb hyper KM, and a higher dose (130 mg/kg/day) produced a much profound effect (Figure 6h) . Likewise, the c-myb level was also significantly reduced in c-myb hyper KM after flavopiridol treatment (Figure 6i) . Notably, flavopiridol treatment (both low and high concentrations) had no obvious effect on the number of myeloid cells in control adult fish (Figure 6h ). Taken together, the above results demonstrate that the c-MYB-targeting drug flavopiridol can effectively relieve MDS in c-myb hyper embryos and adult fish.
DISCUSSION
For decades, high expression of c-MYB has been found to associate with oncogenic activity and poor prognosis in human AMLs, 55 colorectal tumors 56 and adenoid cystic carcinomas. 57 c-MYB duplication was also identified in 8.4-15% human T-ALL.
14,15 The C-terminal truncated c-MYB lacking the negative-regulatory region region was also identified in human angiocentric glioma, 58 AML 59 and a leukemic cell line established from a chronic myeloid leukemia patient in T-cell blast crisis. 16 In this study, we investigated a zebrafish leukemia model with aberrant c-myb hyperactivity. This c-myb hyper model display MDS, AML and ALL phenotypes that resemble the situation of human patients. The neoplastic abnormalities of blood cells in c-myb hyper fish are likely caused by the combined contribution of the duplicated c-Myb-WT and the hyperactive c-Myb-T1, which leads to the upregulation of the same sets of downstream genes including many well-known c-Myb targets involved in cell-cycle progression shown in Table 1 , resulting in the development of neoplastic phenotypes. However, Aberrant c-myb activity and leukemia in zebrafish W Liu et al we cannot exclude the possibility that the hyperactive c-Myb-T1 may regulate additional sets of the downstream targets distinctive from those of c-Myb-WT and further investigation is required to clarify this issue. Nonetheless, our study demonstrates that c-myb plays a crucial role in leukemogenesis in vivo, and the effective response of this model to chemotherapeutic agents will facilitate future drug evaluation and screening.
MDS is the most common hematologic malignancy affecting the elderly, and patients with MDS often progress to AML or ALL. 51 However the mechanisms responsible for the progression from early MDS to ALL or AML remain unclear. The acquisition of additional mutations acts as a factor driving this transition. in some individuals, suggesting c-Myb may be an initiating event for this progression, and clonal evolution or other events were responsible for this progression. The c-myb model thus provides an opportunity to investigate additional risk factors for myeloid and lymphoid leukemias.
Flavopiridol is a MYB-targeting drug that inhibits myb transcriptional elongation. 53 Although flavopiridol has been used for the treatment of lymphocytic leukemia in the clinic, its efficacy in relation to myeloid leukemia remains unclear. Some reports have indicated that flavopiridol, combined with other chemotherapeutic drugs, could be used to treat high-risk or drug-resistant patients with myeloid leukemia. 61 In our study, overaccumulated granulocytes in the c-myb hyper were largely restored after treatment with flavopiridol, suggesting that it may be effective for myeloid leukemias with aberrant c-myb hyperactivity. These results thus provide new evidence for the clinical application of flavopiridol, as well as confirming the use of the c-myb hyper zebrafish disease model as an in vivo system for investigating new chemotherapeutic drugs.
In summary, this study demonstrated that c-myb hyperactivity in zebrafish leads to MDS, AML and ALL, and that this leukemia animal model responds effectively to clinically used chemotherapeutic drugs. These results suggest that c-Myb may be an attractive therapeutic target in certain types of leukemia, and c-myb hyper zebrafish may provide a valuable in vivo drug-screening model for anti-leukemia drugs.
